TODAY'S MARKET INTELLIGENCE
Merck and Moderna's Melanoma Vaccine Trial Positive, Vaccine Themed ETFs Surge
English summary
Merck (MRK.N) and Moderna (MRNA.O) announced positive interim results from the first late-stage trial of their melanoma skin cancer vaccine, driving vaccine ETFs to surge, with several hitting daily limits or rising over 9%.
The English text is machine translated and may require verification against the Chinese version.
Browse today's intelligence